Skip to main content

JADPRO Live 2022 Main banner

Conference Brochure

Tweets by JADPRO Live 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

CE credit available

Pharmacology credit available

150 Views

Treatment Selection for Patients With Relapsed/Refractory Multiple Myeloma

Sunday, November 6, 2022

Location: On-Demand

CE: .75 credit/contact hour

CE credit available

Pharmacology credit available

Speaker(s)

Donna D. Catamero, ANP-BC, OCN®, CCRC

Associate Director, Multiple Myeloma Research
The Mount Sinai Health System
Jersey City, New Jersey, United States

Disclosure: Disclosure(s): No relevant disclosure to display

PDF
Cesar Rodriguez Valdes, MD

Clinical Director
Mount Sinai Tisch Cancer Institute
New York, New York, United States

Disclosure: Disclosure(s): No relevant disclosure to display

Learning Objectives:

Explain novel mechanisms of action in relapsed/refractory multiple myeloma (R/R MM)
Plan strategies to manage unique treatment complications associated with novel treatment modalities in R/R MM
Interpret current clinical trial data in R/R MM
Discuss the implications of novel therapies in R/R MM